Arvinas, Inc
Arvinas, Inc. is a clinical-stage biotechnology company built around its PROTAC protein-degradation platform, which is designed to selectively remove disease-causing proteins rather than just inhibit them. The company’s lead program, vepdegestrant (ARV-471), is an oral estrogen receptor degrader being co-developed with Pfizer for ER+/HER2- breast cancer. Beyond oncology, Arvinas is advancing additional degrader programs in neuroscience and other disease areas, while also building a patent estate around targeted protein degradation. The business is still pre-commercial for its own pipeline, so value creation depends on clinical progress, partnering, and eventual regulatory approvals.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDrug candidates aimed at hormone-driven and other cancer targets, including vepdegestrant and other oncology degraders.
Protein-degradation programs targeting central nervous system and inflammatory disease pathways.
Early-stage internal discovery assets such as pan-KRAS and other preclinical degrader programs.
Upfront payments, milestones, and cost-sharing arrangements from partners such as Pfizer and Genentech.
Customers
Arvinas does not sell commercial medicines broadly today; its current economic counterparties are primarily pharmaceutical partners and, eventually, patients and prescribers if its programs are approved. Pfizer is the most important collaborator because it co-develops vepdegestrant and shares development economics, while also holding marketing authorizations outside the United States. Genentech is another strategic partner through co-owned patent families and licensing arrangements. In the future, the company expects oncology specialists, hospitals, and specialty pharmacies to be the end-market channel for approved products, with commercialization likely supported by partners outside the U.S. and potentially by Arvinas’ own sales force in the U.S. for selected products.
Large pharma partners buy access to Arvinas’ platform, shared development rights, and co-owned assets to de-risk pipeline development and expand their oncology portfolios.
If approved, patients with ER+/HER2- breast cancer and their oncologists would use vepdegestrant and related therapies as targeted treatment options.
Hospitals, cancer centers, and specialty pharmacies would dispense and administer approved products and support access and reimbursement.
Academic and industry partners participate in patent co-ownership, discovery, and licensing arrangements that support the platform and broaden target coverage.
Strategy
Arvinas’ strategy is to convert its PROTAC platform into clinically validated, partnerable medicines, starting with vepdegestrant and then extending into additional oncology and neuroscience programs. The company is prioritizing clinical execution, because proof-of-concept data and regulatory milestones are the main value drivers in a pre-commercial biotech model. It is also using collaborations to share development cost and broaden commercialization reach, especially outside the United States where Pfizer will lead marketing authorization. At the same time, Arvinas is investing in intellectual property, manufacturing relationships, and internal capabilities so it can support future launches and preserve optionality on whether to commercialize certain products itself in the U.S.
The lead asset is the clearest path to first commercial value and validates the PROTAC platform in a major oncology indication.
A diversified set of clinical and preclinical programs reduces dependence on one molecule and expands the platform’s addressable market.
As a clinical-stage company with no product sales, funding discipline is essential to keep multiple programs moving through data readouts.
Patent coverage and collaboration structures are central to monetizing the platform and defending future products.
Geography
Arvinas is headquartered in the United States and currently books sales in the U.S. for vepdegestrant if approved, while Pfizer holds marketing authorizations outside the United States. The company’s commercial model is therefore split between U.S. self-commercialization rights and ex-U.S. partner-led commercialization, which reduces the need for a global sales infrastructure. Its intellectual property footprint is broad, with trademark and patent registrations across the U.S., Europe, Japan, China, and several other jurisdictions, reflecting the global nature of drug development and patent protection. Because the business is still clinical-stage, geography matters more for regulatory rights, IP protection, and future launch sequencing than for current revenue concentration.
Risks
Arvinas faces the classic risks of a clinical-stage biotech company: clinical trial failure, regulatory delay, and the possibility that its product candidates never reach commercialization. The company also depends heavily on collaboration economics, especially with Pfizer, so changes in partner priorities, development decisions, or commercialization plans could materially affect future value. Because it has not yet generated product sales, it will likely need additional capital over time, and unfavorable financing conditions could dilute shareholders or force program delays. More broadly, the company operates in a highly competitive and patent-intensive industry where larger pharmaceutical companies and other protein-degradation developers are pursuing similar targets and where intellectual property disputes can be costly and disruptive.
- Pipeline clinical failureImpact: CriticalLikelihood: High
The company’s value depends on proving that its PROTAC candidates are safe and effective in humans; negative data would reduce or eliminate commercialization prospects.
Exposure - Additional financing needImpact: HighLikelihood: High
The company expects continued operating losses and no near-term product sales, which can require equity issuance or other financing on uncertain terms.
Exposure: Corporate funding runway
- Dependence on collaboration partnersImpact: HighLikelihood: Medium
Pfizer shares development costs and controls ex-U.S. marketing authorization for vepdegestrant, so partner decisions directly affect timing and economics.
Exposure: Vepdegestrant collaboration
- Patent and IP disputesImpact: HighLikelihood: Medium
The business is built on proprietary protein-degradation chemistry and co-owned patent families, making IP challenges a central operating risk.
Exposure: PROTAC platform and target families
Accounting
Judgemental itemsUpfront non-refundable payments, regulatory milestones, and shared development economics must be allocated and recognized over time or at milestones, affecting reported revenue timing.
Impact: Can create large swings in quarterly revenue and margins
Clinical trial accruals, CRO/CMO invoices, and preclinical spend require judgment and can change with program timing.
Impact: Directly affects operating loss and comparability across periods
Equity awards are a meaningful component of employee compensation in biotech and are allocated across functional expense lines.
Impact: Affects both R&D and G&A expense presentation
The company has large NOL and credit carryforwards but records a full valuation allowance because realization is not considered more likely than not.
Impact: Limits recognition of tax benefits on the balance sheet
Similar listed companies
Publicly listed companies with a comparable business focus.
Arcus Biosciences, Inc.
RCUS · Pharmaceutical Preparations
Arcus Biosciences is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and, to a lesser extent, inflammatory and autoimmune diseases.
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
Arbutus Biopharma Corp
ABUS · Pharmaceutical Preparations
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious disease, with its current development efforts centered on chronic hepatitis B.
Oric Pharmaceuticals, Inc.
ORIC · Pharmaceutical Preparations
ORIC Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing cancer therapies designed to overcome treatment resistance.
Aardvark Therapeutics, Inc.
AARD · Pharmaceutical Preparations
Propanc Biopharma, Inc.
PPCB · Pharmaceutical Preparations
Last updated: 24/09/2026